SCHEMBL23723853

SCHEMBL23723853

CN(CC(=O)N(C)C)Cc1nc2c(cnn2C)c(=O)[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 4/20 0.40
TNKS2 Q9H2K2 4/20 0.40
KMT2A Q03164 2/20 0.40
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
ALDH1A1 P00352 4/20 0.39
LMNA P02545 1/20 0.38
MEN1 O00255 1/20 0.36
MAPK1 P28482 1/20 0.36
TDP1 Q9NUW8 2/20 0.35
ESR1 P03372 1/20 0.35
POLB P06746 1/20 0.35
APEX1 P27695 1/20 0.35
BLM P54132 1/20 0.35
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PDE9A O76083 5/20 0.34
PDE1C Q14123 1/20 0.34
PDE1B Q01064 1/20 0.34
PDE5A O76074 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30368715 0.86 KMT2A (0.45) TNKSTNKS2KMT2AALPLALPI
SCHEMBL23723522 0.84 CYP3A4 (0.43) TNKSTNKS2KMT2AALDH1A1MEN1
SCHEMBL23749881 0.83 TNKS (0.47) TNKSTNKS2KMT2AALPLALPI
SCHEMBL23723749 0.83 ALDH1A1 (0.39) KMT2AALPLALPIALDH1A1
SCHEMBL30132076 0.83 ALDH1A1 (0.39) KMT2AALPLALPIALDH1A1
SCHEMBL23723509 0.83 KMT2A (0.41) TNKSTNKS2KMT2AALPLALPI
SCHEMBL23723704 0.82 KMT2A (0.42) TNKSTNKS2KMT2AALPLALPI
SCHEMBL23723707 0.81 TNKS (0.42) TNKSTNKS2KMT2AALPLALPI
SCHEMBL23723639 0.81 ALDH1A1 (0.52) KMT2AALPLALPIALDH1A1LMNA
SCHEMBL30132053 0.81 TNKS (0.42) TNKSTNKS2KMT2AALPLALPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
EP-4100015-A1 COMBINATION THERAPY FOR TREATING MPS1 Gain Therapeutics SA (CH) 2022-12-14 EP disclosed
CN-115397423-A Combination therapy for the treatment of MPS1 增益治疗股份有限公司 2022-11-25 CN disclosed
WO-2021156774-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2021-08-12 WO disclosed
WO-2021156774-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 IDUA, MAN2B1, GBA1 TNKS 3283/4885TNKS2 3462/4885KMT2A 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.